Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -893.25% is 66% below its 5-year average of -538.69%, around the middle of its 5-year range (-1601.21%–-183.06%).
14.10% above its 12-month average of -1039.85%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2019 (2019-12-31): -1601.21%.
EBITDA MARGIN
-893.25%
EBITDA MARGIN AVG TTM
-1039.85%
EBITDA MARGIN AVG 3Y
-776.93%
EBITDA MARGIN AVG 5Y
-538.69%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+14.10%
CURRENT VS 3Y AVG
-14.97%
CURRENT VS 5Y AVG
-65.82%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Vivani Medical, Inc.
Market Cap
$106.93M
EBITDA Margin
-893.25%
TTM Avg
-1039.85%
3Y Avg
-776.93%
5Y Avg
-538.69%
Market Cap
$106.96M
EBITDA Margin
-4735.97%
TTM Avg
-4735.97%
3Y Avg
-4735.97%
5Y Avg
-4735.97%
Market Cap
$106.98M
EBITDA Margin
5.60%
TTM Avg
2.28%
3Y Avg
0.00%
5Y Avg
-2.15%
Market Cap
$107.09M
EBITDA Margin
-6164.17%
TTM Avg
-4620.17%
3Y Avg
-2654.54%
5Y Avg
-2163.85%
Market Cap
$107.17M
EBITDA Margin
-10.96%
TTM Avg
-24.45%
3Y Avg
-32.87%
5Y Avg
-38.11%
Market Cap
$106.52M
EBITDA Margin
-624817.90%
TTM Avg
-624817.90%
3Y Avg
-624817.90%
5Y Avg
-624817.90%
Market Cap
$109.14M
EBITDA Margin
-699.90%
TTM Avg
-1930.94%
3Y Avg
-1689.05%
5Y Avg
-1903.35%
Market Cap
$104.68M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$104.26M
EBITDA Margin
6.31%
TTM Avg
-127.53%
3Y Avg
-89.97%
5Y Avg
-50.55%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vivani Medical, Inc. (VANI) | $106.93M | -893.25% | -1039.85% | -776.93% | -538.69% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $106.96M | -4735.97% | -4735.97% | -4735.97% | -4735.97% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.98M | 5.60% | 2.28% | 0.00% | -2.15% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.09M | -6164.17% | -4620.17% | -2654.54% | -2163.85% |
| Apyx Medical Corporation (APYX)vs › | $107.17M | -10.96% | -24.45% | -32.87% | -38.11% |
| Immunic, Inc. (IMUX)vs › | $106.52M | -624817.90% | -624817.90% | -624817.90% | -624817.90% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $109.14M | -699.90% | -1930.94% | -1689.05% | -1903.35% |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.68M | N/A | N/A | N/A | N/A |
| Definitive Healthcare Corp. (DH)vs › | $104.26M | 6.31% | -127.53% | -89.97% | -50.55% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.30M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
-893.3%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2019-12-31 | -1601.21% |
| 2019-09-30 | -1593.64% |
| 2019-06-30 | -650.86% |
| 2019-03-31 | -857.18% |
| 2018-12-31 | -496.38% |
| 2018-09-30 | -375.73% |
| 2018-06-30 | -413.06% |
| 2018-03-31 | -989.55% |
| 2017-12-31 | -235.48% |
| 2017-09-30 | -411.99% |
| 2017-06-30 | -302.15% |
| 2017-03-31 | -737.56% |
| 2016-12-31 | -1435.24% |
| 2016-09-30 | -711.10% |
| 2016-06-30 | -810.32% |
| 2016-03-31 | -543.40% |
| 2015-12-31 | -227.47% |
| 2015-09-30 | -206.08% |
| 2015-06-30 | -183.06% |
| 2015-03-31 | -286.98% |
| 2014-12-31 | -361.47% |
| 2014-09-30 | -916.31% |
| 2014-06-30 | -898.75% |
| 2014-03-31 | -666.82% |
| 2013-12-31 | -755.54% |
| 2013-09-30 | -1922.80% |
| 2013-06-30 | -1283.46% |
| 2013-03-31 | -1076.59% |
